Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01538472 · ClinicalTrials.gov registry record · Phase 1
Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT01538472: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01538472 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01538472, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to see if high-dose chemotherapy (BEAM) and rituximab, given together with the new drug 90Y Zevalin, followed by a transplant of blood or marrow stem cells is safe. Another goal is to learn if this treatment can help decrease the chances of the cancer coming back.
Interventions
- DRUG BCNU
- DRUG Rituxan
- DRUG Y Zevalin
- DRUG In Zevalin
- DRUG VP -16
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2003-09 |
| Est. Completion | 2011-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01538472
The ClinicalTrials.gov registry entry for NCT01538472 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which BCNU is the first listed.
NCT01538472 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01538472 about?
NCT01538472 is a clinical study titled "Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma". The goal of this clinical research study is to see if high-dose chemotherapy (BEAM) and rituximab, given together with the new drug 90Y Zevalin, followed by a transplant of blood or marrow stem cells is safe. Another goal is to learn if this treatment can help decrease the chances of the cancer comi...
What is the current status of trial NCT01538472?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2003-09. Estimated completion is 2011-11.
What interventions are being tested in trial NCT01538472?
The interventions under investigation include: BCNU (DRUG), Rituxan (DRUG), Y Zevalin (DRUG), In Zevalin (DRUG), VP -16 (DRUG).
Who is sponsoring clinical trial NCT01538472?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.